


**Report of the Trustees and
Unaudited Financial Statements for the Year Ended 31 August 2025
for
Pseudomyxoma Survivor**

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Pseudomyxoma Survivor

**Contents of the Financial Statements
for the Year Ended 31 August 2025**

	Page
Report of the Trustees	1 to 6
Independent Examiner's Report	7
Statement of Financial Activities	8
Balance Sheet	9
Notes to the Financial Statements	10 to 16



PSEUDOMYXOMA SURVIVOR - ANNUAL REPORT TO 31 AUGUST 2025

The trustees present their report with the financial statements of the charity for the year ended 31 August 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OUR OBJECTIVES, AIMS AND ACTIVITIES:

Pseudomyxoma Survivor's main objectives (as set out in the Constitution) are:

- To relieve the sickness, mental and emotional distress of those suffering from pseudomyxoma peritonei (PMP), their families and carers.
- To provide funds to support research into pseudomyxoma peritonei, its causes, treatment and cure and to publish the useful results of such research.
- To promote awareness of pseudomyxoma peritonei.

Notice of bereavement:

It is with deep sorrow that we announced the passing of our esteemed Trustee, **Angela Brook** in April 2025. Angela devoted more than twelve years to the leadership and development of **Pseudomyxoma Survivor**, and we were privileged to benefit from her unwavering commitment and service.

As a patient living with pseudomyxoma peritonei, Angela dedicated her time and expertise to advancing the charity's mission. She played a pivotal role in building and maintaining our website, as well as establishing robust governance systems and procedures essential to the effective management of the charity. Angela's compassion and insight touched countless patients and their families. She provided invaluable support to patients and caregivers, guiding them through unfamiliar and challenging circumstances with empathy and understanding. Her legacy is one of friendship, resilience, and profound dedication to the community she served.

OUR ACHIEVEMENT AND PERFORMANCE:

In order to **support our patients and their caregivers** we have provided:

- A website providing focussed advice, information and support.
- A private Facebook group, which has over 1400 members from across the world. Patients are based in predominantly English-speaking countries with members worldwide.
- Practical as well as emotional support to patients and families through our grant programme and have given financial support to 16 families this year (3 applications were declined). A total of £14,500 was paid.
- The ongoing provision of a Buddy Scheme to provide one-to-one support to patients and caregivers around the world.
- Access to a family flat in Manchester, to support the families of those patients being treated at The Christie. The flat is managed by the Christie Charitable Fund on our behalf. The flat contains personalised blankets and information about Pseudomyxoma Survivor. Funding was provided in previous years and will be done so again as required.
- Ward toiletries to The Christie and Basingstoke.
- Support to patient days at both the Christie and Basingstoke hospitals

In order to **promote awareness of pseudomyxoma peritonei**, Trustees have:

- Attended the 14th International Congress on Peritoneal Surface Malignancies in Lyon, France. The conference was a joint meeting of the Peritoneal Surface Oncology Group International (PSOGI) and the International Society for the Study of Pleura and Peritoneum (ISSPP) and dedicated to improving the treatment and survival of peritoneal metastases.
- Attended various sessions hosted by National Voices, Findacure and data studies
- Attended Cancer52 meetings
- Promoted Rare Disease Day (28th February 2025)
- Published weekly posts on all social media channels regarding the disease
- Supported many competitors and volunteers, by providing merchandise for a wide variety of events
- Provided specialist leaflets for the hospitals to hand out to patients.

We have contributed funds to the following **research programmes** during the year to 31 August 2025:

- The team at the Peritoneal Malignancy Institute at Basingstoke & North Hampshire Hospitals NHS Foundation Trust are undertaking a research programme to analyse patient data to craft a machine learning predictive model for recurrence and survival, to guide clinical decisions and treatment plans.
- We are continuing to monitor the Norwegian GNAS Vaccine Trial at Oslo University [Oslo University GNAS research programme](#). We are delighted to confirm this has now been approved for human patient trials and the first patient has received their vaccine.

We continue to provide pro-bono support of research trials and studies:

- Assistance with an application towards a dietary study in Australia etc.

Pseudomyxoma Survivor's purpose and its activities contribute to the public benefit through activities to support these objectives. We are here to help patients understand the treatment options, provide leaflets and online resources that they can trust. We represent the PMP community through links with other rare disease charities, by attending conferences and by supporting events organised to raise awareness of the disease.

We take pride in the stewardship of our donations, which we demonstrated through this year with our committed registration with the Fundraising Regulator. Pseudomyxoma Survivor has paid due regard to the Charity Commission's general guidance on public benefit when reviewing its aims and objectives and in planning its future activities.

Charitable activities:

Pseudomyxoma is entirely reliant upon donations for our income and due to our very generous supporters, we have received £124,369 in donations and other income.

We are indebted to all of our fundraisers and their families and friends for their generosity.

Our Facebook support group goes from strength to strength, and we have continued support for the pseudomyxoma peritonei community on RareConnect, a Eurordis initiative that provides a multi-lingual support platform for rare diseases and on the platform operated by Cancer Research.

We have continued to develop a close working relationship with the teams at the Basingstoke and North Hampshire Hospital and The Christie Hospital in Manchester, which allows us to better support patients, and identify research opportunities.

Once again we were able to retain our status with the Great Non Profits organisation.

FINANCIAL REVIEW

Financial position:

We are extremely pleased that we have total funds of £257,787 at the end of the financial year. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

Pseudomyxoma Survivor's income and expenditure is relatively small and consequently the charity does not have sufficient funds to invest in longer term investments such as stocks and shares.

Reserves policy:

Through prudence in our activities, we are now able to ensure that we have a reserve in future years. We will do this through our plan which ensures the charity has reserves to cover our patient grant scheme, basic resources required to keep us 'in business' and to attend conferences where we can represent the voice of the PMP community going forward, for 24 months. With appropriate and controlled governance procedures in place, the trustees continue to be confident that grants and awareness activities can increase the value of the charity to the community.

During the year to 31 August 2025, 12 months' expenditure equated to £31,931, plus the expenditure on research of £36,000 and family grants of £14,500, totalling £82,431. Whereas reserves at the period end totalled £257,787 and reserves excluding designated funds totalled £121,287.

We have designated expenditure as at the year ended 31 August 2025 of £136,500 (2024: £79,098) which will be spent in accordance with our charitable objectives, aims and activities which are detailed in the Trustee Report. All opportunities will be scrutinised in accordance with our due diligence procedures before any expenditure is committed.

Future plans:

With very grateful thanks to our very generous donors, we have plans in place to financially support the following initiatives during the financial year 2025/2026:

- The ongoing provision of family and caregivers accommodation at the Christie Hospital in Manchester.
- We will continue to promote the Family Grants to give financial support where appropriate.
- We will continue to monitor the team at the Basingstoke Hospital on the research programme which aims to analyse patient data to craft a machine learning predictive model for recurrence and survival, to guide clinical decisions and treatment plans.
- The team at the Christie Hospital in Manchester are in very early stage discussions with us regarding a new research project for which funding of £100,000 may be requested.
- We will have discussions with the Christie Hospital in Manchester to continue to monitor and support the prehabilitation study.
- We will keep in touch with all of our patients and caregivers especially when we know that they are going through stressful situations.
- We will continue to closely monitor the Norwegian GNAS research programme, which has now been approved and entered into patient trials.

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2025

STRUCTURE, GOVERNANCE AND MANAGEMENT

Governing document

The charity is controlled by its governing document, a deed of trust and constitutes an unincorporated charity.

Recruitment and appointment of new trustees

Trustees are appointed by the existing trustees. We are delighted that Madeleine Lomas has been appointed a Trustee with effect 23 June 2025.

Organisational structure

In addition to the Trustees we have a group of volunteers who actively undertake the day to day administration of the Facebook group and a further 60 who volunteer as Buddys on the Buddy scheme.

Our people

Pseudomyxoma Survivor relies entirely on the dedication of volunteers to deliver and manage the activities of our charity. We are fortunate to have five active Trustees, each bringing a wealth of skills and experience that will help us grow and thrive in the years ahead. Their commitment and generosity in giving their time to support the charity is invaluable.

We would also like to extend our heartfelt thanks to all of our volunteers this financial year, particularly those who moderate the Patient group and manage the buddies scheme.

A special acknowledgment goes to Mark Ponsford, who has led an online patient discussion forum every week since 2018. This remarkable level of commitment to the charity and to fellow patients is deeply appreciated.

REFERENCE AND ADMINISTRATIVE DETAILS

Registered Charity number

1143642

Principal address

Appletree House
Mill Lane, Ellerton
York
YO42 4PA

Trustees


Mrs S Oliver
Mr T Brill
Mrs C Fletcher
Mrs A C Salisbury
Mrs A B Brook (deceased 2.4.25)
Ms M C Lomas (appointed 23.6.25)

Independent Examiner

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Pseudomyxoma Survivor
Report of the Trustees
for the Year Ended 31 August 2025

Approved by order of the board of trustees on30 December 2025 and signed on its behalf by:


.....
Mrs A C Salisbury - Trustee

**Independent Examiner's Report to the Trustees of
Pseudomyxoma Survivor**

Independent examiner's report to the trustees of Pseudomyxoma Survivor

I report to the charity trustees on my examination of the accounts of Pseudomyxoma Survivor (the Trust) for the year ended 31 August 2025.

Responsibilities and basis of report

As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act').

I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act.

Independent examiner's statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Laura Drew

Harris Lacey and Swain
Suite 1
The Riverside Building
Hessle
East Yorkshire
HU13 0DZ

Date: *6th January 2026*

Pseudomyxoma Survivor

**Statement of Financial Activities
for the Year Ended 31 August 2025**

	Notes	Unrestricted funds £	Restricted funds £	2025 Total funds £	2024 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies		120,001	1,895	121,896	64,216
Investment income	2	2,473	-	2,473	-
Total		<u>122,474</u>	<u>1,895</u>	<u>124,369</u>	<u>64,216</u>
EXPENDITURE ON					
Raising funds	3	9,648	-	9,648	9,293
Charitable activities	4				
Charitable activities		19,883	-	19,883	12,621
Grant making		14,655	36,325	50,980	53,513
Support costs		1,920	-	1,920	1,830
Total		<u>46,106</u>	<u>36,325</u>	<u>82,431</u>	<u>77,257</u>
NET INCOME/(EXPENDITURE)		76,368	(34,430)	41,938	(13,041)
Transfers between funds	12	<u>(28,955)</u>	<u>28,955</u>	<u>-</u>	<u>-</u>
Net movement in funds		47,413	(5,475)	41,938	(13,041)
RECONCILIATION OF FUNDS					
Total funds brought forward		210,374	5,475	215,849	228,890
TOTAL FUNDS CARRIED FORWARD		<u><u>257,787</u></u>	<u><u>-</u></u>	<u><u>257,787</u></u>	<u><u>215,849</u></u>


The notes form part of these financial statements

Pseudomyxoma Survivor

**Balance Sheet
31 August 2025**

	Notes	Unrestricted funds £	Restricted funds £	2025 Total funds £	2024 Total funds £
CURRENT ASSETS					
Debtors	10	1,172	-	1,172	1,993
Cash at bank		258,535	-	258,535	217,382
		<u>259,707</u>	<u>-</u>	<u>259,707</u>	<u>219,375</u>
CREDITORS					
Amounts falling due within one year	11	(1,920)	-	(1,920)	(3,526)
		<u>257,787</u>	<u>-</u>	<u>257,787</u>	<u>215,849</u>
NET CURRENT ASSETS					
		<u>257,787</u>	<u>-</u>	<u>257,787</u>	<u>215,849</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>257,787</u>	<u>-</u>	<u>257,787</u>	<u>215,849</u>
NET ASSETS		<u>257,787</u>	<u>-</u>	<u>257,787</u>	<u>215,849</u>
FUNDS	12				
Unrestricted funds				257,787	210,374
Restricted funds				-	5,475
TOTAL FUNDS				<u>257,787</u>	<u>215,849</u>

The financial statements were approved by the Board of Trustees and authorised for issue on ...30 December 2025.... and were signed on its behalf by:


.....
Mrs A C Salisbury - Trustee

The notes form part of these financial statements

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

Income received for services provided is accounted for on an accruals basis.

Cash donations, gifts and legacies are included in full in the income and expenditure account as they are received. Any significant non-cash donations are included in the income and expenditure account at the trustees' estimate of their market value when received. The value of voluntary help is not included in the accounts.

Grants and other funding of a revenue nature are deferred and released to the income and expenditure account over the period to which they relate.

Bank interest is included in the income and expenditure account on an accruals basis.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

Estimates and judgements

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Although these estimates are based on the Directors' best knowledge of the amount, events or actions, actual results ultimately differ from these estimates. The Directors do not consider there to be any material estimates and judgements.

Notes to the Financial Statements - continued
for the Year Ended 31 August 2025

1. ACCOUNTING POLICIES - continued

Financial instruments

The company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments, including trade and other debtors and creditors, are initially recognised at transaction value and subsequently measured at their settlement value.

2. INVESTMENT INCOME

	2025	2024
	£	£
Deposit account interest	2,473	-

3. RAISING FUNDS

Raising donations and legacies

	2025	2024
	£	£
Just Giving	2,173	1,325
Costs of generating funds	7,475	7,968
	9,648	9,293

4. CHARITABLE ACTIVITIES COSTS

	Direct Costs £	Grant funding of activities (see note 5) £	Support costs (see note 6) £	Totals £
Charitable activities	19,883	-	-	19,883
Grant making	-	50,980	-	50,980
Support costs	-	-	1,920	1,920
	19,883	50,980	1,920	72,783

5. GRANTS PAYABLE

	2025	2024
	£	£
Grant making	50,980	53,513
The total grants paid to institutions during the year was as follows:		
	2025	2024
	£	£
Grants given	36,000	46,000

A grant totalling £36,000 was awarded to The Peritoneal Malignancy Institute at Basingstoke Hospital towards research to analyse patient data to craft a Machine Learning predictive model for recurrence and survival, to guide clinical decisions and treatment plans.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

6. SUPPORT COSTS

	Governance costs
	£
Support costs	1,920
	<u> </u>

Support costs, included in the above, are as follows:

	2025	2024
	Support costs	Total activities
	£	£
Independent examination	1,920	1,830
	<u> </u>	<u> </u>

7. TRUSTEES' REMUNERATION AND BENEFITS

There was trustees' remuneration totalling £9,000 (2024 - £8,820) but no other benefits for the year ended 31 August 2025 or other benefits for the year ended 31 August 2024.

The remuneration was received by Mrs S Oliver for their role as the Charity's administrator, after much consideration by the board as to how to fill this role. This was recorded in the Charity's board meeting minutes.

Trustees' expenses

There were no trustees' expenses paid for the year ended 31 August 2025 nor for the year ended 31 August 2024.

8. STAFF COSTS

There were no staff costs for the year ended 31 August 2025 nor for the year ended 31 August 2024.

The average number of employees during the year was NIL (2024 - NIL).

No employees received emoluments in excess of £60,000.

9. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted funds	Restricted funds	Total funds
	£	£	£
INCOME AND ENDOWMENTS FROM			
Donations and legacies	58,741	5,475	64,216
	<u> </u>	<u> </u>	<u> </u>
EXPENDITURE ON			
Raising funds	9,293	-	9,293
Charitable activities			
Charitable activities	12,621	-	12,621
Grant making	22,513	31,000	53,513
Support costs	1,830	-	1,830
	<u> </u>	<u> </u>	<u> </u>
Total	46,257	31,000	77,257
	<u> </u>	<u> </u>	<u> </u>
NET INCOME/(EXPENDITURE)	12,484	(25,525)	(13,041)

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

9. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted funds £	Restricted funds £	Total funds £
Transfers between funds	(31,000)	31,000	-
Net movement in funds	(18,516)	5,475	(13,041)
RECONCILIATION OF FUNDS			
Total funds brought forward	228,890	-	228,890
TOTAL FUNDS CARRIED FORWARD	<u>210,374</u>	<u>5,475</u>	<u>215,849</u>

10. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025 £	2024 £
Other debtors	1,025	1,846
Prepayments and accrued income	147	147
	<u>1,172</u>	<u>1,993</u>

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2025 £	2024 £
Trade creditors	-	1,696
Other creditors	1,920	1,830
	<u>1,920</u>	<u>3,526</u>

12. MOVEMENT IN FUNDS

	At 1.9.24 £	Net movement in funds £	Transfers between funds £	At 31.8.25 £
Unrestricted funds				
General fund	131,276	76,368	(86,357)	121,287
Designated fund	79,098	-	57,402	136,500
	<u>210,374</u>	<u>76,368</u>	<u>(28,955)</u>	<u>257,787</u>
Restricted funds				
Research fund	5,475	(34,430)	28,955	-
TOTAL FUNDS	<u>215,849</u>	<u>41,938</u>	<u>-</u>	<u>257,787</u>

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

12. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	122,474	(46,106)	76,368
Restricted funds			
Research fund	1,570	(36,000)	(34,430)
Family grants	325	(325)	-
	<u>1,895</u>	<u>(36,325)</u>	<u>(34,430)</u>
TOTAL FUNDS	<u>124,369</u>	<u>(82,431)</u>	<u>41,938</u>

Comparatives for movement in funds

	At 1.9.23 £	Net movement in funds £	Transfers between funds £	At 31.8.24 £
Unrestricted funds				
General fund	111,390	12,484	7,402	131,276
Designated fund	117,500	-	(38,402)	79,098
	<u>228,890</u>	<u>12,484</u>	<u>(31,000)</u>	<u>210,374</u>
Restricted funds				
Research fund	-	(25,525)	31,000	5,475
	<u>228,890</u>	<u>(13,041)</u>	<u>-</u>	<u>215,849</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	58,741	(46,257)	12,484
Restricted funds			
Research fund	5,475	(31,000)	(25,525)
TOTAL FUNDS	<u>64,216</u>	<u>(77,257)</u>	<u>(13,041)</u>

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

12. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.9.23 £	Net movement in funds £	Transfers between funds £	At 31.8.25 £
Unrestricted funds				
General fund	111,390	88,852	(78,955)	121,287
Designated fund	117,500	-	19,000	136,500
	<u>228,890</u>	<u>88,852</u>	<u>(59,955)</u>	<u>257,787</u>
Restricted funds				
Research fund	-	(59,955)	59,955	-
	<u>-</u>	<u>(59,955)</u>	<u>59,955</u>	<u>-</u>
TOTAL FUNDS	<u>228,890</u>	<u>28,897</u>	<u>-</u>	<u>257,787</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	181,215	(92,363)	88,852
Restricted funds			
Research fund	7,045	(67,000)	(59,955)
Family grants	325	(325)	-
	<u>7,370</u>	<u>(67,325)</u>	<u>(59,955)</u>
TOTAL FUNDS	<u>188,585</u>	<u>(159,688)</u>	<u>28,897</u>

Restricted funds relate to the provision of research funding.

Transfers between funds

Fund transfers during the year relate to the transfers of previously designated funds to cover actual spending in the year.

The designated fund relates to monies set aside for committed future spending.

Pseudomyxoma Survivor

**Notes to the Financial Statements - continued
for the Year Ended 31 August 2025**

13. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 31 August 2025.